Forian’s (FORA) Buy Rating Reaffirmed at Roth Mkm

Forian (NASDAQ:FORA)‘s stock had its “buy” rating reiterated by equities researchers at Roth Mkm in a report issued on Thursday,Benzinga reports. They currently have a $5.00 price objective on the stock. Roth Mkm’s price objective points to a potential upside of 148.76% from the stock’s current price.

Forian Price Performance

NASDAQ FORA traded down $0.03 on Thursday, reaching $2.01. 1,538 shares of the company’s stock traded hands, compared to its average volume of 15,665. The stock has a market cap of $62.53 million, a PE ratio of 40.20 and a beta of 1.09. Forian has a 12 month low of $2.00 and a 12 month high of $4.15. The stock has a 50-day simple moving average of $2.15 and a 200 day simple moving average of $2.44.

Forian (NASDAQ:FORA) last released its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $5.26 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share.

Institutional Investors Weigh In On Forian

A number of hedge funds and other institutional investors have recently modified their holdings of FORA. Caprock Group LLC purchased a new position in Forian in the 2nd quarter worth approximately $230,000. Canton Hathaway LLC raised its holdings in Forian by 2.3% during the 3rd quarter. Canton Hathaway LLC now owns 269,650 shares of the company’s stock valued at $582,000 after buying an additional 6,125 shares during the last quarter. Finally, Elser Financial Planning Inc purchased a new stake in Forian during the 2nd quarter valued at $1,885,000. Institutional investors own 19.25% of the company’s stock.

About Forian

Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.